Acute GVHD (aGVHD) is an important risk factor for predicting the incidence or severity of chronic GVHD (cGVHD). Transplant outcome can be influenced by the onset time of aGVHD in patients who have received allogeneic PBSC transplants (PBSCTs). The medical records of 134 patients who survived more than 3 months after myeloablative allogeneic PBSCT were retrospectively reviewed. In all, 38 patients (28.4%) developed grade II-IV aGVHD before day þ 28 (early aGVHD) and 25 patients (18.7%) after day þ 28 (late aGVHD). The 5-year cumulative incidence of cGVHD was 78.9% in the early-aGVHD group and 56.6% in the late-aGVHD group (P ¼ 0.034). The 5-year OS was 51.0% for the early-aGVHD and 80.8% for the late-aGVHD group (P ¼ 0.406). Infection was the primary cause of death for the early-aGVHD group (51.4 vs 16.7%, P ¼ 0.017), whereas relapse of the primary disease was higher among the patients with late aGVHD, although this was statistically insignificant (58.3 vs 25.7%, P ¼ 0.309). In a multivariate analysis, early aGVHD was identified as a risk factor for developing cGVHD (hazard ratio (HR) 2.278, P ¼ 0.004). The development of aGVHD early after allogeneic PBSCT increased the risk of cGVHD and infection-related death rate when compared with the late onset of aGVHD.
Introduction
Although recent advances in SCT procedures have contributed to improved outcomes after allo-SCT, GVHD remains a major complication in recipients. 1 Thus, understanding the predictors for the development of severe GVHD can help in the management of recipients in the allogeneic setting. [2] [3] [4] [5] [6] The severity of acute GVHD (aGVHD) can be affected by the toxicity of the preparative regimen, the breakdown of mucosal barriers, increased release of inflammatory cytokines and so on. 7, 8 Previous studies have also reported that high levels of inflammatory cytokines measured around the first month after transplantation are more frequently associated with the early development of aGVHD rather than late development of aGVHD. [9] [10] [11] These results therefore imply that aGVHD occurring early after transplantation may have a different effect on transplant outcome. Accordingly, the current study provides a comparative analysis of transplant outcomes for patients who developed aGVHD before day þ 28 and after day þ 28 of allogeneic PBSC transplantation (PBSCT).
Methods

Patients and transplantation procedures
This study conducted a retrospective review of data for 134 patients who survived more than 3 months after undergoing allogeneic PBSCT for hematological diseases between April 1998 and October 2007 at three centers: Kyungpook National University Hospital, Chonnam National University Hwasun Hospital and Pusan National University Hospital in Korea. The median follow-up time was 553 days (range 100-3974 days) after transplantation, and all patients received a myeloablative PBSCT.
For the myeloablative BU/fludarabine (BU/FLU) regimen, the BU (Busulfex, Orphan Medical Inc., Minnetonka, MN, USA) was infused i.v. at 3.2 mg/kg/day for 4 days (total 12.8 mg/kg/day, days -7 to -3), whereas the FLU was given i.v. at 30 mg/m 2 for 6 days (total 180 mg/m 2 /day, days -7 to -2). For the BU/CY (Bu/Cy2) regimen, BU was administered orally at 4 mg/day every 6 h (total 16 mg/day) or infused i.v. at 3.2 mg/kg/day for 4 days (total 12.8 mg/ kg/day, days -7 to -3), followed by CY (120 mg/m 2 ) for 2 days according to the protocol used in previous studies. HLA typing was performed using serologic testing for class I alleles (A, B and Cw) and DNA-based typing for HLA class II molecules (DRB1).
Prophylactic antibiotics consisted of ciprofloxacin (250 mg twice daily, orally), metronidazole (500 mg three times daily, orally) and fluconazole (100 mg once daily, orally) beginning with the initiation of conditioning. Acyclovir (600 mg twice daily, orally) was started from day -1 and cotrimoxazole started after engraftment. Ursodeoxycholinic acid was used for veno-occlusive disease (VOD) prophylaxis beginning with the initiation of conditioning.
GVHD
Grade II-IV aGVHD that developed before day þ 28 after transplantation was defined as 'early aGVHD', whereas grade II-IV aGVHD that developed after day þ 28 was defined as 'late aGVHD'. Diagnosis and grading of aGVHD were performed according to the consensus conference on aGVHD. 12 Acute GVHD prophylaxis consisted of MTX and cyclosporine. Cyclosporine was initially administered at a dose of 5 mg/kg/day through continuous infusion on day -1, reduced to a dose of 2.5 mg/kg/day through continuous infusion on day þ 7 and then changed to a dose of 3 mg/kg/ day twice daily orally when tolerated. Meanwhile, MTX was administered at a dose of 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6 and 11. The last dose of MTX was omitted when mucositis over grade 4 or renal impairment was observed. The frontline treatment for aGVHD was the addition of prednisone (1-2 mg/kg/day), and when a patient with aGVHD did not respond to steroids and cyclosporine, cyclosporine was switched to tacrolimus. Chronic GVHD was diagnosed and graded based on published criteria. 13 The initial treatment for cGVHD was prednisone (1-2 mg/kg/day) and the reintroduction of cyclosporine or tacrolimus to the therapeutic range. If further immunosuppressive agents were needed to control the cGVHD, the salvage regimen included mycophenolate mofetile, antithymocyte globulin, 14 weekly MTX 15 or a combination therapy. Mycophenolate mofetile was added at a dose of 1.5 or 2 g daily and steroids were tapered in refractory cases, in which tapering was a dose reduction of 0.2 mg/kg/week. The dose of mycophenolate mofetile was escalated to 2 g/day if patients had progressive GVHD.
Definitions
The day of stem cell infusion was defined as day 0. Myeloid engraftment was defined as the first day of achieving an ANC of X0.5 Â 10 9 /l for 3 consecutive days, whereas plt engraftment was defined as the first day of achieving plts of X20 Â 10 9 /l without requiring a transfusion for 3 consecutive days. High-risk diseases were defined as any disease relapsing after chemotherapy or auto-SCT, acute leukemia exceeding first CR, Ph þ ALL, advanced-phase CML or primary refractory or multiple relapsed malignancies.
Statistical analysis
Continuous variables were compared using a two-sample t-test, whereas the categorical data were analyzed using a chi-square test. OS was defined as time from transplantation until death from any cause and was analyzed using the Kaplan-Meyer test; both groups were compared using a log-rank test or Breslow test. The cumulative incidence of cGVHD was calculated using Gray's method, considering death or relapse without cGVHD as competing risks, which was carried out using the 'cmprsk' package from R statistical software (R Foundation for Statistical Computing, Vienna, Austria; available at http://www.r-project. org). A time-dependent Cox's regression model was used to determine the clinical predictors for the development of cGVHD. Factors with a P-value of p0.05 on univariate analysis were included in the multivariate analysis. For the statistical analyses, SPSS software version 13 (SPSS Inc., Chicago, IL, USA) and R statistical software 2.8.0 were used. A P-value of o0.05 was considered significant.
Results
Patient characteristics
Acute GVHD developed at a median of 27 days (range 3-85 days) after transplantation. A total of 63 patients were diagnosed as grade II-IV aGVHD, with early aGVHD occurring in 38 patients and late aGVHD in 25 patients. No differences in clinical factors were found between the earlyand late-aGVHD groups, except for the conditioning regimens received (Table 1 ). The early-aGVHD group received more BU/CY or CY/TBI conditioning (n ¼ 30, 78.9%) than BU/FLU conditioning (n ¼ 8, 21.1%), whereas the late-aGVHD group received more myeloablative BU/FLU conditioning (n ¼ 15, 60.0%) than BU/CY or CY/TBI conditioning (n ¼ 10, 40.0%; Po0.001). Thus, when adjusted with other pre-transplant clinical factors (recipient age, sex, high-risk group, donor type, HLA mismatch, sex and ABO disparity, GVHD prophylaxis and in vivo T-cell depletion), BU/FLU conditioning was found to be related to late aGVHD (odds ratio 5.625, 95% confidence interval (CI) 1.840-17.194; P ¼ 0.002). Patient characteristics are summarized in Table 1 .
Transplantation outcomes
The median onset of early aGVHD was 18 days (range 3-27 days), whereas that of late aGVHD was 41 days (range 29-85 days). No difference was found in the incidence of severe aGVHD (grade III-IV) between the early-aGVHD (34.2%) and late-aGVHD (32.0%) groups (P ¼ 0.856, Table 2 ).
The 5-year OS rates were 69.0, 51.0 and 80.8% for the patients with grade 0-I aGVHD, early aGVHD and late aGVHD, respectively (P ¼ 0.406) (Figure 1 ). Although no significant differences were found between the early-and lateaGVHD groups in terms of OS (P ¼ 0.218), the causes of death did differ between the two groups. Infection was the primary cause of death in the early-aGVHD group (n ¼ 9, 52.9%), whereas relapse of the primary disease was more common among the patients with late aGVHD (n ¼ 4, 100%; Table 2 ). In the nine patients in the early-aGVHD group for whom infection was the primary cause of death, two patients had limited cGVHD and seven had extensive cGVHD.
Chronic GVHD
The median time of onset of cGVHD was 168 days (range 100-1600 days) in the early-aGVHD group and 171 Limited and extensive cGVHD occurred in 10 (26.3%) and 20 patients (52.6%) in the early-aGVHD group, and 6 (24.0%) and 7 patients (28.0%) with late aGVHD, respectively (P ¼ 0.060; Table 2 ). The cumulative incidence of cGVHD was higher among the patients with early aGVHD than those with late aGVHD (Figure 2 ). The 5-year cumulative incidence of extensive cGVHD was 32.4, 55.8 and 33.2% for the patients with grade 0-I aGVHD, early aGVHD and late aGVHD, respectively (P ¼ 0.014). When comparing the early-and late-aGVHD groups, the early-aGVHD group showed a higher cumulative incidence of extensive cGVHD (P ¼ 0.038).
Factors affecting development of cGVHD
This study also analyzed the factors predicting the development of cGVHD and included the following pretransplant clinical factors in the analysis: recipient age (436 vs p36) and sex, pre-transplant risk group, donor type (sibling vs unrelated), HLA disparity, ABO disparity, sex disparity, in vivo T-cell depletion, GVHD prophylaxis, conditioning regimen and aGVHD group (early vs late aGVHD).
On univariate analysis, a recipient age of more than 36 years (hazard ratio (HR) 1.647, P ¼ 0.039) and early aGVHD (HR 2.353, P ¼ 0.001) were identified as factors related to a higher incidence of extensive cGVHD, whereas the patients who received BU/FLU conditioning showed a lower incidence of extensive cGVHD (HR 0.305, Po0.001). Meanwhile, on multivariate analysis, early aGVHD (HR 2.278, 95% CI 1.474-3.521, P ¼ 0.004) and non-FLU-based conditioning (HR 0.309, 95% CI 0.192-0.497, Po0.001) were identified as factors predicting the development of extensive cGVHD (Table 3) P ¼ 0.025) were also identified as factors related to a higher incidence of extensive cGVHD (Table 3) .
Discussion
In this study involving an allogeneic PBSCT setting, the early development of aGVHD resulted in an increased incidence of cGVHD and decreased survival (Figures 1 and 2 ). During the early-phase post transplantation, the pre-transplant conditioning produces increased systemic inflammatory cytokine and endotoxin levels that activate the residual host immune system and may have divergent roles in the kinetics of GVHD development. 7, [16] [17] [18] [19] By influencing the DCs and skewing the cytokine milieu toward a more immunosuppressive microenvironment, inflammatory cytokines facilitate the induction of an early T-cell response, thereby providing temporal differences in the case of aGVHD onset. 16, [20] [21] [22] [23] Previous studies have already found that the early release of serum cytokines and host immune system activation are correlated with the early development of aGVHD. [24] [25] [26] [27] [28] Donor T-cell recognition of host alloantigens activates T cells and further stimulates cytokine production and the recruitment of secondary effectors, such as macrophages and natural killer cells, to the target organs, especially to the gastrointestinal tract. These damage tissues, resulting in leakage of endotoxins across the damaged mucosal barriers and further exacerbation of the cytokine cascade. The transferred T cells also remain functional after infusion, being capable of producing IFN-g in response to antigenspecific stimulation. 29 Especially in an allogeneic PBSCT setting, the onset of aGVHD may vary according to the dose of CD3 þ or CD34 þ cells. Furthermore, the use of FLU, which is widespread for allogeneic PBSCT, can have a different effect on the onset of immunologic manifestations in recipients than do a BU/CY or TBI-based regimen. It is well known that decreased regimen-related toxicity results in an overall decreased incidence of aGVHD during the first 3 months in the case of reduced-intensity allo-SCT, whereas cGVHD and OS are similar in the case of myeloablative and reduced-intensity SCT. 30 In this study, the FLU-based conditioning was related to a lower incidence of cGVHD (Table 3 ) and higher incidence of late aGVHD (OR 5.625, 95% CI 1.840-17.194, P ¼ 0.002). A previous study by the current authors comparing a myeloablative BU/FLU regimen and BU/ CY regimen reported that the myeloablative BU/FLU group showed significantly superior outcomes in terms of severe aGVHD and OS. 31 Iravani et al. 32 also showed that a myeloablative BU/FLU regimen resulted in the same efficacy and a lower TRM when compared with a BU/CY2 regimen. Previous studies showed that organ damage because of conditioning and the leakage of lipopolysaccharide from intestinal mucosa represented some of the main causes of the development of GVHD. The reduced host tissue damage and excellent immunosuppressive effect of FLU seemed to lead to a lower incidence or decreased severity of GVHD in the BU/FLU group.
In the early-aGVHD group, the primary cause of death was infection related, whereas in the late-aGVHD group it was relapse related ( Table 2 ). In the context of immunologic vulnerability early after transplantation, the early use of an immunosuppressant delays immune recovery, thereby increasing the risk of infection. 8, 20, 33 In another study by the current authors, early development of GVHD was found to be connected to a higher incidence of infectionrelated death and lower incidence of relapse-related death. 34 According to our previous study, patients with hyperacute GVHD experienced a significantly lower incidence of relapse compared with patients without hyperacute GVHD. However, in the current setting, no statistical significance was observed between the earlyand late-aGVHD groups in terms of relapse (P ¼ 0.790). This may have been because the only patients included in the current study were those who survived more than 3 months after allo-SCT. Diaconescu et al. 18 reported that the breakdown of mucosal barriers in ablative conditioning may lead to bacterial translocation in immunocompromised hosts, thereby explaining the increased risk of mucositis-associated bacteremias in their patients. Thus, patients developing aGVHD early after transplantation may require thorough infection surveillance and prolonged infection prophylaxis. Although there is no clear explanation as to why the patient group with an early onset of aGVHD had a lower incidence of relapse, the early onset of aGVHD may have been due to a higher degree of immunologic difference between recipient and donor, leading to a higher incidence of cGVHD and more effective graft-versus-tumor effect.
In conclusion, early aGVHD occurring before day þ 28 after transplantation would seem to be a negative prognostic indicator with regard to the incidence of cGVHD. It requires close monitoring with regard to the onset of cGVHD. 
